During the recent session, Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.44. At the last check today, the stock’s price was $4.75, reflecting an intraday gain of 1.39% or $0.07. The 52-week high for the ALDX share is $11.97, that puts it down -152.0 from that peak though still a striking 70.11% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $279.77M, and the average intraday trading volume over the past 10 days was 0.84 million shares, and the average trade volume was 556.59K shares over the past three months.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Aldeyra Therapeutics Inc (ALDX) registered a 1.39% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.39% in intraday trading to $4.75, hitting a weekly high. The stock’s 5-day price performance is 45.26%, and it has moved by 20.87% in 30 days. Based on these gigs, the overall price performance for the year is -52.12%. The short interest in Aldeyra Therapeutics Inc (NASDAQ:ALDX) is 1.83 million shares and it means that shorts have 3.26 day(s) to cover.
Aldeyra Therapeutics Inc (ALDX) estimates and forecasts
Statistics show that Aldeyra Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Aldeyra Therapeutics Inc (ALDX) shares have gone down -15.33% during the last six months, with a year-to-date growth rate more than the industry average at 78.13% against 9.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 59.30% this quarter and then jump 13.30% in the quarter after that. An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.70%. While earnings are projected to return 70.80% in 2024.
ALDX Dividends
Aldeyra Therapeutics Inc is due to release its next quarterly earnings between May 02 and May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Aldeyra Therapeutics Inc insiders own 2.01% of total outstanding shares while institutional holders control 60.64%, with the float percentage being 61.89%. Perceptive Advisors Llc is the largest shareholder of the company, while 140 institutions own stock in it. As of Jun 29, 2023, the company held over 11.35 million shares (or 19.37% of all shares), a total value of $95.23 million in shares.
The next largest institutional holding, with 3.23 million shares, is of Blackrock Inc.’s that is approximately 5.51% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $27.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Aldeyra Therapeutics Inc (ALDX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 2.13 million shares. This amounts to just over 3.64 percent of the company’s overall shares, with a $15.91 million market value. The same data shows that the other fund manager holds slightly less at 1.7 million, or about 2.90% of the stock, which is worth about $14.24 million.
